Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean G Buchanan

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Cancer Cell|December 13, 2017
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor AbemaciclibXueqian Gong, Lacey M Litchfield, Yue Webster, et al.
Cancer Discovery|May 15, 2020
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast CancerSeth A Wander, Ofir Cohen, Xueqian Gong, et al.
Molecular Cancer Therapeutics|November 26, 2009
SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivoSean G Buchanan, Jorg Hendle, Patrick S Lee, et al.
Cancer Discovery|October 31, 2018
Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the <i>RB1</i> Tumor Suppressor GeneXueqian Gong, Jian Du, Stephen H Parsons, et al.
Molecular Cancer Therapeutics|September 19, 2019
Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor EfficacyJian Du, Lei Yan, Raquel Torres, et al.
Nature Communications|May 4, 2026
Characterization of KRAS<sup>G12C</sup> inhibitor olomorasib single-agent and combination with activity in KRAS<sup>G12C</sup>-mutant modelsShengbin Peng, Youyan Zhang, Xi Lin, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Cancer Cell|December 13, 2017
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor AbemaciclibXueqian Gong, Lacey M Litchfield, Yue Webster, et al.
Cancer Discovery|May 15, 2020
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast CancerSeth A Wander, Ofir Cohen, Xueqian Gong, et al.
Molecular Cancer Therapeutics|November 26, 2009
SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivoSean G Buchanan, Jorg Hendle, Patrick S Lee, et al.
Cancer Discovery|October 31, 2018
Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the <i>RB1</i> Tumor Suppressor GeneXueqian Gong, Jian Du, Stephen H Parsons, et al.
Molecular Cancer Therapeutics|September 19, 2019
Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor EfficacyJian Du, Lei Yan, Raquel Torres, et al.
Nature Communications|May 4, 2026
Characterization of KRAS<sup>G12C</sup> inhibitor olomorasib single-agent and combination with activity in KRAS<sup>G12C</sup>-mutant modelsShengbin Peng, Youyan Zhang, Xi Lin, et al.
Pageof 2